Literature DB >> 22907349

Selection of stable scFv antibodies by phage display.

Eeva-Christine Brockmann1.   

Abstract

ScFv fragments are popular recombinant antibody formats but often suffer from limited stability. Phage display is a powerful tool in antibody engineering and applicable also for stability selection. ScFv variants with improved stability can be selected from large randomly mutated phage displayed libraries with a specific antigen after the unstable variants have been inactivated by heat or GdmCl. Irreversible scFv denaturation, which is a prerequisite for efficient selection, is achieved by combining denaturation with reduction of the intradomain disulfide bonds. Repeated selection cycles of increasing stringency result in enrichment of stabilized scFv fragments. Procedures for constructing a randomly mutated scFv library by error-prone PCR and phage display selection for enrichment of stable scFv antibodies from the library are described here.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22907349     DOI: 10.1007/978-1-61779-974-7_7

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  3 in total

1.  Co-evolution of affinity and stability of grafted amyloid-motif domain antibodies.

Authors:  Mark C Julian; Christine C Lee; Kathryn E Tiller; Lilia A Rabia; Evan K Day; Arthur J Schick; Peter M Tessier
Journal:  Protein Eng Des Sel       Date:  2015-09-19       Impact factor: 1.650

2.  A statistical framework for analyzing deep mutational scanning data.

Authors:  Alan F Rubin; Hannah Gelman; Nathan Lucas; Sandra M Bajjalieh; Anthony T Papenfuss; Terence P Speed; Douglas M Fowler
Journal:  Genome Biol       Date:  2017-08-07       Impact factor: 13.583

3.  The antigenicity and cholesteroid nature of mycolic acids determined by recombinant chicken antibodies.

Authors:  Heena Ranchod; Fortunate Ndlandla; Yolandy Lemmer; Mervyn Beukes; Johann Niebuhr; Juma Al-Dulayymi; Susan Wemmer; Jeanni Fehrsen; Mark Baird; Jan Verschoor
Journal:  PLoS One       Date:  2018-08-09       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.